U.S. patent number 3,856,469 [Application Number 05/320,374] was granted by the patent office on 1974-12-24 for interferant removal from amphetamine immunoassay.
This patent grant is currently assigned to Syva Corporation. Invention is credited to Richard S. Schneider, Edwin F. Ullman.
United States Patent |
3,856,469 |
Schneider , et al. |
December 24, 1974 |
INTERFERANT REMOVAL FROM AMPHETAMINE IMMUNOASSAY
Abstract
A method for removing .beta.-hydroxyamine compounds as an
interferant from immunoassays, where like compounds, such as
amphetamine, methamphetamine, and the like are to be determined.
The sample, for example, urine is treated with aqueous periodate at
a mildly basic pH for a time sufficient to remove the
.beta.-hydroxyamine as an interferant, the pH being maintained by
an ammonium hydroxide. The sample may then be used in assays for
the determination of amphetamine or like compounds without
interference from the .beta.-hydroxyamine compound.
Inventors: |
Schneider; Richard S.
(Sunnyvale, CA), Ullman; Edwin F. (Atherton, CA) |
Assignee: |
Syva Corporation (Palo Alto,
CA)
|
Family
ID: |
23246127 |
Appl.
No.: |
05/320,374 |
Filed: |
January 2, 1973 |
Current U.S.
Class: |
436/536; 250/303;
436/803; 436/815; 436/825; 564/381; 252/187.2; 436/816;
436/826 |
Current CPC
Class: |
G01N
33/946 (20130101); Y10S 436/826 (20130101); Y10S
436/815 (20130101); Y10S 436/825 (20130101); Y10S
436/803 (20130101); Y10S 436/816 (20130101) |
Current International
Class: |
G01N
33/94 (20060101); G01n 023/00 (); G01n 031/02 ();
G01n 033/16 () |
Field of
Search: |
;23/23B ;252/186,187R
;424/12 |
References Cited
[Referenced By]
U.S. Patent Documents
Other References
L Chafetz, J. Pharm. Sci., 52, (12), 1193-1195, (1963). .
Chemical Abstracts, 63: 8942f, (1965)..
|
Primary Examiner: Wolk; Morris O.
Assistant Examiner: Marantz; Sidney
Claims
What is claimed is:
1. In an assay method for determining aralkyl amines, wherein
1-aralkyl .beta.-hydroxyamines interfere, the improvement which
comprises: treating the sample to be assayed at a pH greater than
about 8 with an amount of aqueous periodate solution sufficient to
remove the hydroxyamine interferant wherein said pH is maintained
by the presence of an ammonium hydroxide.
2. A method according to claim 1, wherein the concentration of said
periodate is in the range of about 10.sup.-.sup.3 to 10.sup.-.sup.7
moles/ml.
3. A method according to claim 1, wherein said periodate is at a
concentration in the range of about 10.sup.-.sup.4 to
10.sup.-.sup.6 moles/ml.
4. A method according to claim 1, wherein the concentration of said
ammonium hydroxide is in an amount of from 2 to 20 times the
concentration of periodate and said ammonium hydroxide is
tetraalkyl ammonium hydroxide.
5. In a method for carrying out immunoassays to detect amphetamine
or methamphetamine, the improvement which comprises: treating the
sample to be assayed with aqueous periodate solution at a
concentration in the range of about 10.sup.-.sup.4 to
10.sup.-.sup.6 moles/ml in the presence of an ammonium hydroxide in
an amount sufficient to provide a pH in the range of about 8 to
9.
6. A method according to claim 5, wherein said ammonium hydroxide
is tetramethyl ammonium hydroxide.
7. A method according to claim 5, wherein said ammonium hydroxide
is NH.sub.4 OH.
8. A method according to claim 5, wherein said treating is carried
out at a temperature in the range of about 10.degree. to 40.degree.
C and for a time in the range of about 1 to 10 minutes.
9. An aqueous solution which is 0.05 to 0.5 M in periodate and 0.5
to 2 M in tetraalkylammonium hydroxide of from four to eight carbon
atoms.
10. A solution according to claim 9, wherein said
tetraalkylammonium hydroxide is tetramethylammonium hydroxide and
said periodate ranges from 0.05 to 0.3 M in concentration.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention
There is frequent need for accurate and reliable determination of
amphetamine, methamphetamine or like materials. Since amphetamine
is a drug of abuse, there is the police function of determining
whether a person has taken amphetamine. There is also the medicinal
function of determining the amount of amphetamine in a biological
fluid.
Phenylpropanolamine is a common drug sold over the counter, which
is taken in relatively large dosages. Because of the relatively
high concentration of the phenylpropanolamine in biological fluids
when used and the structural similarity of the phenylpropanolamine
to amphetamine, the phenylpropanolamine obscures the detection of
the amphetamine, for example, in chromatography or by providing a
false signal, as in immunoassays.
Immunoassays are based on employing a receptor, usually an
antibody, which is capable of recognizing or distinguishing a
particular chemical structure. By employing techniques which
distinguish between those compounds which bind to the receptor and
those compounds which do not, the compound recognized by the
receptor can be determined, qualitatively or quantitatively.
Radioimmunoassays which allow for a competition between a
radioactively labelled compound and the compound to be assayed have
been known for a long time. More recently, two new and unique
methods have been developed. The first method employs an electron
spin resonance technique, entitled FRAT, supplied by Syva Corp. The
second technique employs enzyme labelled with a compound which
simulates the compound to be assayed, and is called EMIT.sup.TM,
also supplied by Syva Corp. The accuracy of these techniques is
dependent upon, among other variables, the ability for the receptor
- the antibody - to recognize a specific compound. In preparing
antibodies to a specific compound, the compound is bonded to an
antigen and the antigen injected in an animal. This results in the
production of antibodies which recognize the compound. Compounds
which have this property are referred to as haptens.
While antibodies show high specificity for particular geometry or
spatial configuration and a particular distribution of polar and
non-polar groups, antibodies will frequently recognize similar
compounds to a lesser degree and infrequently to a greater degree.
This recognition of compounds other than the compound of interest
is referred to as cross-reactivity.
Where there is undesirable cross-reactivity, and the cross-reacting
compound is sufficiently prevalent in the samples to be determined,
so as to be of concern, it is necessary to find some way to remove
or change the compound, so that the antibody will not recognize it
or bind the compound. It is found that with derivatives of
.beta.-phenethyl amine, e.g., amphetamine and methamphetamine,
.beta.-hydroxyphenethyl amine compounds are strong interferants.
Since compounds such as phenylpropanolamine are frequently in
decongestants sold over the counter, it is necessary to be able to
distinguish between amphetamine, for example, and
phenylpropanolamine. The method employed for allowing the antibody
to distinguish between the two must not interfere with the assay
system. Furthermore, it must not affect the phenethylamine
derivative, so as to modify the response of the antibody to the
phenethylamine derivative. Nor may the method chosen affect the
label, so as to give a spurious result.
2. Description of the Prior Art
A description of the free radical assay technique can be found in
U.S. Pat. No. 3,690,834, issued Sept. 12, 1972. A description of
the enzyme technique may be found in copending application Ser. No.
143,609, filed May 14, 1971, now abandoned. A description of the
radioimmunoassay technique may be found in numerous texts, such as
Kirkham, et al., Radioimmunoassay Methods, European Workshop,
September 1970, Churchill, London 1971; Ferrari, Gazz. Chim. Ital.
92 22 (1962) reports the formation of crystalline
tetramethylammonium periodate.
SUMMARY OF THE INVENTION
A medium to be assayed for a phenethylamine derivative is combined
with a small amount of an aqueous periodate solution at a mild
temperature and mildly basic pH for a sufficient time to modify any
.beta.-hydroxy-.beta.-phenethylamine derivative, which acts as an
interferant, so as to destroy its interfering effect. The sample is
then used in the determination without interference from the
.beta.-hydroxyamine. The method finds particular use with
immunoassays.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Liquid media suspected of containing a .beta.-phenethylamine
derivative, such as amphetamine or methamphetamine are treated with
a small amount of periodate at a mildly basic pH (.gtoreq.8) for a
sufficient time to modify any aralkyl .beta.-phenethylamines, so as
to prevent obtaining a spurious result because of the presence of
phenylpropanolamine or the like compound. That is, those compounds
having vicinal hydroxyamines and an aliphatic group bonded to a
phenyl ring. These interferants are normally of from eight to 10
carbon atoms.
The sample may then be used in a normal way in any of the variety
of determinations, such as thin layer chromatography, immunoassays,
e.g., radioimmunoassay, the electron spin resonance technique,
referred to as FRAT or the enzyme technique, referred to as
EMIT.sup.TM. The immunoassays will usually be carried out at a pH
below 8, usually in the range of 5.0 to 7.5, more usually 5.5 to
7.0.
The medium may be any source suspected of containing the
phenethylamine. Of particular interest are physiological media,
such as blood serum, saliva, and urine, particularly urine. Any of
the normal treatments given to the fluid may be carried out prior
to the periodate treatment. When the medium has been properly
prepared, it is combined with the periodate at a mildly basic pH
and allowed to stand, with mild agitation if desired, for a
sufficient time to modify or destroy the interfering substances
sensitive to the periodate treatment.
The amount of periodate will vary depending on the particular
medium and the suspected degree of contamination with interferants,
but will normally be in the range of about 10.sup.-.sup.3 to
10.sup.-.sup.7 moles/ml, and more usually about 10.sup.-.sup.4 to
10.sup.-.sup.6 moles/ml, and particularly about 10.sup.-.sup.5
moles/ml.
The basic pH, usually in the range of 8 to 10, can be achieved with
a variety of bases. The periodate forms complex ions with varying
pH and these complex ions are of varying solubility in aqueous
systems. Conveniently, ammonium hydroxide (ammonium includes
quaternary ammonium hydroxides of from 1 to 12, usually one to six
carbon atoms) is used to achieve the desired pH. Preferred
hydroxides are ammonium hydroxide (NH.sub.4 OH) and tetraalkyl
ammonium hydroxide of from four to eight carbon atoms. The ammonium
hydroxide will be present in amounts sufficient to provide a pH of
the treated medium in the range of about 8 to 10 usually 8 to 9.
Usually the amount in moles of ammonium hydroxide will be 2 to 20
times that of moles of periodate, more usually from about 5 to 15
times that of the periodate. Conveniently, a reagent solution can
be prepared which is 0.01 to 0.5, more usually 0.05 to 0.3 M in
periodate and 0.25 to 2, more usually 0.5 to 1.5 M in ammonium
hydroxide.
It is found that at concentrations of periodate useful as reagents
for combining with physiological fluids, short shelf lives are
obtained with the usual alkali metal cations at the basic pH. With
tetraalkylammonium cations, long shelf lives are obtained, so that
the reagents can be prepared, stored and shipped without any
precipitate forming.
The temperature of the periodate treatment will normally be in the
range of about 0.degree. to 40.degree.C, more usually from about
10.degree. to 30.degree.C, and the assays can be conveniently
carried out at ambient temperatures. The time for treatment will
usually be as short as possible to obtain the desired results and
will usually be from about 1 to 10 minutes, more usually about 5
minutes.
The periodate is conveniently employed as an alkali metal
periodate, particularly sodium and potassium, and preferably
sodium. The quaternary ammonium hydroxides are illustrated by
tetraethylammonium hydroxide, diethyldimethylammonium hydroxide,
N,N-dimethyl piperidinium hydroxide, N-methyl pyridinium hydroxide,
and the like. Usually, the quaternary ammonium hydroxide will be
free of unsaturation, both aliphatic and aromatic.
After treatment with the periodate, the sample is ready to be used.
In immunoassays, the assay solution is normally sufficiently
buffered to control the pH. The immunoassay solution will normally
be at a pH of 7.5 or below. At these pHs, the periodate is found
not to adversely affect the various reagents or interfere with the
immunoassay determination.
In other types of determination, e.g., chromatography -- thin layer
chromatography -- the sample may be used directly.
To demonstrate the subject invention, a number of urine samples
were tested, employing the enzyme assay system. In carrying out the
test, 20.mu.l of a reagent which was 0.13 M in sodium periodate and
1.2 F in tetramethylammonium hydroxide was combined with urine (100
.mu.l) and allowed to stand for five minutes.
In carrying out the assay, N-carboxymethyl-amphetamine was employed
for determining the amphetamine present. N-carboxymethylamphetamine
was conjugated with lysozyme as follows:
(All temperatures are in Centigrade)
N-carboxymethylamphetamine (25 mg, 0.133mM) was suspended in 1.8 ml
of dry dioxane at 40.degree.. Phosgene (12.5 volume percent in
benzene) (0.715 ml) was added in one portion. The reaction mixture
was stirred at 40.degree. for 3.5 hours before an additional 0.2 ml
of phosgene (12.5 volume percent in benzene) was added. After
stirring an additional 30 minutes, the solution became homogeneous.
The solvent was removed in vacuo at 25.degree. in the hood. An
additional 0.70 ml of dry dioxane was added for use in the next
step.
The cold dioxane solution of the above product was added dropwise
over 5 minutes to a stirred, cold (0.degree.) solution of 200 mg
sodium bicarbonate and 100 mg lysozyme in 10 ml water. The milky
reaction mixture was stirred at 4.degree. for 48 hours and dialyzed
against 1.1 changed 3 times daily over a 48 hour period. The
residue was lyophilized.
The assay is carried out by combining 0.2 ml of M. luteus (30 mg)
in 50 ml of 0.05 M Tris-maleate of pH 6 and 20.lambda. of
amphetamine antibody (1.3 .times. 10.sup.-.sup.5 M in binding
sites), followed by the addition of 80.lambda. of the urine sample.
The mixture was then diluted with 0.5 ml of a solution of the above
modified enzyme to provide a ratio of binding sites to moles of
lysozyme of 1.5:1. The reaction mixture was then aspirated into the
spectrometer and the decrease in optical density measured at 436 nm
for 40 seconds at 30.degree..
A standard urine sample was employed to which a variety of
different materials were added, and the results determined with and
without the periodate treatment. The following table indicates the
results:
TABLE I ______________________________________ RATE Without
IO.sub.4 With IO.sub.4 Treatment Treatment
______________________________________ URINE 46 47
______________________________________ 1.0 .mu.g/ml amphetamine 64
55 5.0 .mu.g/ml amphetamine 95 85 50.0 .mu.g/ml amphetamine 173 152
50 .mu.g/ml ephedrine 117 45 100 .mu.g/ml ephedrine 132 47 50
.mu.g/ml phenylpropa- 99 46 nolamine 100 .mu.g/ml phenylpropa- 137
46 nolamine ______________________________________
The periodate is very effective in removing phenylpropanolamine and
ephedrine as an interferant. While the result for amphetamine
changes with periodate treatment, a different standard curve can be
obtained, which is reproducible, so that the same results for the
amphetamine can be obtained with and without periodate treatment by
using a different standard curve, where an interferant is not
present.
Samples of lyophylized urine containing 0.0 and 1.0 .mu.g/ml of
amphetamine were employed. Employing the assay technique described
above, the 0.0 sample gave readings of 48; 50; 50 OD/min, and the
1.0 .mu.g/ml sample gave readings of 59; 61 OD/min. When 200 .mu.l
of aqueous sample was combined with 10 .mu.l of 0.5 g/ml sodium
periodate and 10 .mu.l ammonium hydroxide (10 wt percent in water)
the results for the two samples were: 0.0 .mu.g/ml-48; 50; and 1.0
.mu.g/ml-62; 57. When aqueous phenylpropanolamine at a
concentration of 55 .mu.g/ml was employed the reading was 70; 81
OD/min. After treatment of the sample with the ammonium hydroxide
and periodate and waiting five minutes, the readings were 52; 52
OD/min.
The further demonstrate the effect of the sodium periodate, 100
.mu.l of the 1.0 .mu.g/ml amphetamine solution was combined with 15
.mu.l of 0.5 g/10 ml aqueous sodium periodate and 5 .mu.l of 10 wt
percent aqueous sodium hydroxide. The reading was 60 OD/min after 2
minutes. When the determination was repeated replacing the 100
.mu.l of 1.0 .mu.g aqueous amphetamine solution with 100 .mu.l
aqueous phenylpropanolamine solution (55 .mu.g/ml) the readings
were 41; 46 OD/min. This is equivalent to background.
A series of urine samples were obtained which were verified to
contain amphetamine by gas-liquid chromatography. The samples were
then tested according to the above procedure by the enzyme
techniques, as well as by the electron spin resonance
technique.
In the FRAT assay, N'-2' ,2' ,5'
,5'-tetramethylpyrrolidinyl-1'-oxyl 1-phenyl-2-propylaminoacetamide
is the spin label reagent and is employed at a concentration of
2.85 .times. 10.sup.-.sup.6 M, with the mole ratio of spin label to
antibody (based on binding sites) of 0.95. The concentration of
borate buffer at pH 8.0 is 0.18 M. The sample is treated with a
small amount of dichromate to destroy any ascorbic acid and 20
.mu.l of sample is added to 5 .mu.l of antibody solution and 5
.mu.l of the spin label at the appropriate buffer concentration.
The sample is then taken up in an ESR capillary tube and read in an
ESR spectrometer and the amphetamine concentration determined by
comparison with a standard.
The following table indicates the results.
TABLE II
__________________________________________________________________________
FRAT* EMIT* .mu.g/ml GLC Result .mu.g/ml .mu.g/ml Without IO.sub.4
With IO.sub.4
__________________________________________________________________________
Ampheta- Methamphe- mine tamine
__________________________________________________________________________
16 9.6 6.7 8.0 1 18 8.7 6.7 6.5 14 41 35 34 9 400-700 35 34 >50
5 5 3.8 3.8 5.7 3 14 8.3 10.2 9 18.5 9.4 8.8 14 19.5 14.0 15.0 1 24
33 27.5 32.0 21 37 1.95 2.6 3.0 4 3.7 3.0 3.1 45 >100 >50
>50 550 >100 >50 >50
__________________________________________________________________________
*Total of amphetamine and methamphetamine
The above results show that the periodate does not affect the
results obtained with amphetamine. Therefore, the amphetamine can
be accurately assayed for by removing interferants such as
phenylpropanolamine without affecting the assay for the
.beta.-phenethylamine derivative.
Although the foregoing invention has been described in some detail
by way of illustration and example for purposes of clarity of
understanding, it will be obvious that certain changes and
modifications may be practiced within the scope of the invention,
as limited only by the scope of the appended claims.
* * * * *